A team of Duke Health clinicians that include faculty from the Department of Medicine are working diligently in a collaborative effort to enroll patients in a randomized, controlled trial, testing a novel antibody treatment for COVID-19.
The photograph of blue, pink and neon-green globes that Christina Barkauskas, MD, keeps on her desk inside the Nanaline Duke Research Building looks like a string of glowing holiday lights. That is, until she decodes it.
Produced with a confocal microscope, the image is evidence of new insight into how some lung tissue repairs itself. It captures type 2 epithelial cells within alveoli functioning like stem or progenitor cells by giving rise to type 1 epithelial cells, which contribute to tissue repair.
For Dr. Barkauskas, this is not knowledge for knowledge’s sake. It’s data needed to better serve patients with often-lethal idiopathic pulmonary fibrosis.
Fourteen faculty from the Department of Medicine were chosen as Duke Health Scholars and Duke Health Fellows. This inaugural program was created with a transfer of funds from the Duke University Health System. Its aim is to support the research efforts and enhance the academic success of early to mid-career clinician-scientists in School of Medicine clinical departments.
Christina Barkauskas, MD, assistant professor of medicine (Pulmo
Medicine Research Conference will take place Fri., March 27 at 12 p.m. in Duke Hospital 2002 with a presentation by Christina Barkauskas, MD, medical instructor in the Division of Pulmonary, Allergy and Critical Care Medicine.
Dr. Barkauskas will present Understanding the cell biology of pulmonary fibrosis.